Evidence map›Paper›PMID 34782707›Full record

ArticlePediatric research2023

Acute lymphoblastic leukemia in children and SALL4 and BMI-1 gene expression.

Hossam Hodeib, Doaa El Amrousy, Amira Youssef, Rasha Khedr, Hassan Al-Asy, Ahmed Shabana, Shimaa Elnemr, Dina Abdelhai

Abstract read
PubMed Publisher
In one paragraph

Article in Pediatric research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Aberrant stem cell and developmental programs in pediatric leukemia.Frontiers in cell and developmental biology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Hossam HodeibClinical Pathology Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
Doaa El AmrousyPediatric Department, Faculty of Medicine, Tanta University, Tanta, Egypt. doaamoha@yahoo.com.
Amira YoussefClinical Pathology Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
Rasha KhedrClinical Oncology Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
Hassan Al-AsyPediatric Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
Ahmed ShabanaPediatric Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
Shimaa ElnemrPediatric Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
Dina AbdelhaiClinical Pathology Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
Tanta University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSal-like protein 4 transcription factor (SALL4) and B cell-specific Moloney murine leukemia virus integration site 1 (BMI-1) gene were reported to cause treatment failure and relapse in several malignancies. We aimed to evaluate the prognostic value of SALL4 and BMI-1 in children with acute lymphoblastic leukemia (ALL).

methodsThis prospective cohort study was carried out on 60 children with ALL as the patient group and 60 age- and sex-matched children as the control group. We evaluated the expression pattern of both SALL4 and BMI-1 genes in the peripheral blood using real-time reverse transcriptase-polymerase chain reaction in children with ALL at initial diagnosis before chemotherapy. We followed up with the patient group for 2 years for relapse or death.

resultsBoth SALL4 and BMI-1 were overexpressed in ALL children compared to the control group. Moreover, the expression of SALL4 and BMI-1 in patients with relapse was significantly higher than those with complete remission. The best cut-off of SALL4 and BMI-1 to predict relapse were >2.21 and 0.55 yielding sensitivity of 92.3% and 84.6%, respectively. Patients with overexpression of SALL4 and BMI-1 had significantly shorter overall and disease-free survival.

conclusionsSALL4 and BMI-1 could be useful prognostic markers in children with ALL to predict relapse.

Indexed as

Precursor Cell Lymphoblastic Leukemia-LymphomaTranscription FactorsBody Mass IndexChildGene ExpressionHumansPolycomb Repressive Complex 1Prospective StudiesRecurrenceBMI1 protein, humanPolycomb Repressive Complex 1SALL4 protein, humanTranscription Factors

Identifiers

PMID34782707
OpenAlexW3214114667

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.